Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04985968




Registration number
NCT04985968
Ethics application status
Date submitted
22/07/2021
Date registered
2/08/2021
Date last updated
27/12/2023

Titles & IDs
Public title
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
Scientific title
A Randomised Double-Blind Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Cobitolimod as an Induction and Maintenance Therapy in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
Secondary ID [1] 0 0
CSUC-01/21
Universal Trial Number (UTN)
Trial acronym
CONCLUDE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ulcerative Colitis 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Cobitolimod 250 mg
Treatment: Drugs - Cobitolimod 500 mg
Treatment: Drugs - Placebo

Experimental: Cobitolimod 250 mg - Dose of 250 mg cobitolimod
2 treatments during induction study and subsequently every third week

Experimental: Cobitolimod 500 mg - Dose of 500 mg cobitolimod
2 treatments during induction study and subsequently every third week

Placebo Comparator: Placebo - Dose of Placebo
2 treatments during induction study and subsequently every third week


Treatment: Drugs: Cobitolimod 250 mg
Rectal administration

Treatment: Drugs: Cobitolimod 500 mg
Rectal administration

Treatment: Drugs: Placebo
Rectal administration
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Induction - Proportion of participants with clinical remission.
Timepoint [1] 0 0
Week 6
Primary outcome [2] 0 0
Maintenance - Proportion of participants with clinical remission.
Timepoint [2] 0 0
Week 52
Secondary outcome [1] 0 0
Induction - Proportion of participants with endoscopic improvement.
Timepoint [1] 0 0
Week 6
Secondary outcome [2] 0 0
Induction - Proportion of participants with symptomatic remission.
Timepoint [2] 0 0
Week 6
Secondary outcome [3] 0 0
Induction - Proportion of participants with clinical response.
Timepoint [3] 0 0
Week 6
Secondary outcome [4] 0 0
Induction - Proportion of participants with normalisation of stool frequency.
Timepoint [4] 0 0
Week 6
Secondary outcome [5] 0 0
Induction - Proportion of participants with absence of rectal bleeding.
Timepoint [5] 0 0
Week 6
Secondary outcome [6] 0 0
Induction - Mean stool frequency.
Timepoint [6] 0 0
Week 6
Secondary outcome [7] 0 0
Induction - Proportion of participants with histologic improvement.
Timepoint [7] 0 0
Week 6
Secondary outcome [8] 0 0
Induction - Proportion of participants with histologic remission.
Timepoint [8] 0 0
Week 6
Secondary outcome [9] 0 0
Induction - Proportion of participants with mucosal healing.
Timepoint [9] 0 0
Week 6
Secondary outcome [10] 0 0
Induction - Mean ln-transformed faecal calprotectin.
Timepoint [10] 0 0
Week 6
Secondary outcome [11] 0 0
Induction - Mean 3-component and 4-component Mayo scores.
Timepoint [11] 0 0
Week 6
Secondary outcome [12] 0 0
Induction - Mean IBDQ total score.
Timepoint [12] 0 0
Week 6
Secondary outcome [13] 0 0
Induction - Proportion of participants with an improvement in IBDQ total score.
Timepoint [13] 0 0
Week 6
Secondary outcome [14] 0 0
Maintenance - Proportion of participants with endoscopic improvement.
Timepoint [14] 0 0
Week 52
Secondary outcome [15] 0 0
Maintenance - Proportion of participants with clinical remission and steroid-free.
Timepoint [15] 0 0
Week 52
Secondary outcome [16] 0 0
Maintenance - Proportion of participants with clinical remission among those who achieved clinical remission
Timepoint [16] 0 0
Week 52
Secondary outcome [17] 0 0
Maintenance - Proportion of participants with symptomatic remission.
Timepoint [17] 0 0
Week 52
Secondary outcome [18] 0 0
Maintenance - Proportion of participants with histologic improvement.
Timepoint [18] 0 0
Week 52
Secondary outcome [19] 0 0
Maintenance - Proportion of participants with histologic remission.
Timepoint [19] 0 0
Week 52
Secondary outcome [20] 0 0
Maintenance - Proportion of participants with mucosal healing.
Timepoint [20] 0 0
Week 52
Secondary outcome [21] 0 0
Maintenance - Proportion of participants with clinical response.
Timepoint [21] 0 0
Week 52
Secondary outcome [22] 0 0
Maintenance - Proportion of participants with absence of rectal bleeding.
Timepoint [22] 0 0
Week 52
Secondary outcome [23] 0 0
Maintenance - Proportion of participants with normalisation of stool frequency.
Timepoint [23] 0 0
Week 52
Secondary outcome [24] 0 0
Maintenance - Mean stool frequency.
Timepoint [24] 0 0
Week 52
Secondary outcome [25] 0 0
Maintenance - Mean ln-transformed faecal calprotectin.
Timepoint [25] 0 0
Week 52
Secondary outcome [26] 0 0
Maintenance - Mean 3-component and 4-component Mayo scores.
Timepoint [26] 0 0
Week 52
Secondary outcome [27] 0 0
Maintenance - Mean IBDQ total score.
Timepoint [27] 0 0
Week 52
Secondary outcome [28] 0 0
Maintenance - Proportion of participants with an improvement in IBDQ total score.
Timepoint [28] 0 0
Week 52

Eligibility
Key inclusion criteria
Inclusion Criteria Induction:

- Male or female = 18 years of age.

- Established diagnosis of UC.

- Moderate to severe active left-sided UC assessed by central reading.

- Have inadequate response, loss of response or be intolerant of at least one of the
following treatments: Oral GCS, AZA/6-MP, Biologics, JAK-inhibitors, or other approved
advanced therapies for UC.

- Allowed to receive a therapeutic dose of the following UC drugs during the study: Oral
GCS therapy (=20 mg prednisone or equivalent/day) , Oral 5-ASA/SP compounds, AZA/6-MP.

- Ability to understand the treatment, willingness to comply with all study
requirements, and ability to provide informed consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria Induction:

- Suspicion of differential diagnosis.

- Acute fulminant UC and/or signs of systemic toxicity.

- UC limited to the rectum or extending beyond the splenic flexure.

- Have failed treatment with more than three advanced therapies of two different
therapeutic classes.

- Have had surgery for treatment of UC.

- History of malignancy, unless treated with no relapse of the disease and = 5 years
since last treatment (cured).

- History or presence of any clinically significant disorder.

- Concomitant treatment with cyclosporine, methotrexate, tacrolimus, or advanced
therapies or similar immunosuppressants and immunomodulators.

- Treatment with rectal GCS, 5-ASA/SP or tacrolimus.

- Long-term treatment (>14 days) with antibiotics or NSAIDs .

- Serious known active infection including history of latent or active tuberculosis.

- Gastrointestinal infections including positive Clostridium difficile stool assay.

- Females who are lactating or have a positive serum pregnancy test.

- Women of childbearing potential not using highly effective contraceptive methods.

- Concurrent participation in another clinical study.

- Previous exposure to cobitolimod.

Inclusion Criteria Maintenance:

- Participants are eligible to be included in the maintenance study if they have
achieved clinical response at week 6 and have adhered to the protocol procedures of
the induction study.

Exclusion Criteria Maintenance:

- Participants will not be eligible for the maintenance study if they are not willing to
comply with all further study requirements.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
24/11/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
20/12/2023
Sample size
Target
Accrual to date
Final
171
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Monash Health - Clayton
Recruitment hospital [2] 0 0
St Vincent's Hospital Melbourne - Fitzroy
Recruitment hospital [3] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [4] 0 0
Royal Melbourne Hospital - Parkville
Recruitment hospital [5] 0 0
Mater Health Services - South Brisbane
Recruitment hospital [6] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 0 0
- Clayton
Recruitment postcode(s) [2] 0 0
- Fitzroy
Recruitment postcode(s) [3] 0 0
- Melbourne
Recruitment postcode(s) [4] 0 0
- Parkville
Recruitment postcode(s) [5] 0 0
- South Brisbane
Recruitment postcode(s) [6] 0 0
- Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Kansas
Country [4] 0 0
United States of America
State/province [4] 0 0
Michigan
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
North Carolina
Country [7] 0 0
United States of America
State/province [7] 0 0
Ohio
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
United States of America
State/province [9] 0 0
Virginia
Country [10] 0 0
United States of America
State/province [10] 0 0
Wisconsin
Country [11] 0 0
Austria
State/province [11] 0 0
Innsbruck
Country [12] 0 0
Austria
State/province [12] 0 0
Klagenfurt
Country [13] 0 0
Austria
State/province [13] 0 0
Salzburg
Country [14] 0 0
Austria
State/province [14] 0 0
Wien
Country [15] 0 0
Belgium
State/province [15] 0 0
Antwerpen
Country [16] 0 0
Belgium
State/province [16] 0 0
Bonheiden
Country [17] 0 0
Belgium
State/province [17] 0 0
Brussels
Country [18] 0 0
Belgium
State/province [18] 0 0
Gent
Country [19] 0 0
Belgium
State/province [19] 0 0
Kortrijk
Country [20] 0 0
Belgium
State/province [20] 0 0
Roeselare
Country [21] 0 0
Bosnia and Herzegovina
State/province [21] 0 0
Banja Luka
Country [22] 0 0
Bosnia and Herzegovina
State/province [22] 0 0
Foca
Country [23] 0 0
Bosnia and Herzegovina
State/province [23] 0 0
Sarajevo
Country [24] 0 0
Bosnia and Herzegovina
State/province [24] 0 0
Tesanj
Country [25] 0 0
Bosnia and Herzegovina
State/province [25] 0 0
Tuzla
Country [26] 0 0
Bosnia and Herzegovina
State/province [26] 0 0
Zenica
Country [27] 0 0
Brazil
State/province [27] 0 0
Goiania
Country [28] 0 0
Brazil
State/province [28] 0 0
Porto Alegre
Country [29] 0 0
Brazil
State/province [29] 0 0
Rio De Janeiro
Country [30] 0 0
Brazil
State/province [30] 0 0
Santo Andre
Country [31] 0 0
Brazil
State/province [31] 0 0
Sao Jose do Rio Preto
Country [32] 0 0
Brazil
State/province [32] 0 0
São Bernardo do Campo
Country [33] 0 0
Canada
State/province [33] 0 0
Hamilton
Country [34] 0 0
Canada
State/province [34] 0 0
Montréal
Country [35] 0 0
Canada
State/province [35] 0 0
Saskatoon
Country [36] 0 0
Croatia
State/province [36] 0 0
Bjelovar
Country [37] 0 0
Croatia
State/province [37] 0 0
Osijek
Country [38] 0 0
Croatia
State/province [38] 0 0
Pula
Country [39] 0 0
Croatia
State/province [39] 0 0
Zadar
Country [40] 0 0
Croatia
State/province [40] 0 0
Zagreb
Country [41] 0 0
Denmark
State/province [41] 0 0
Aalborg
Country [42] 0 0
Denmark
State/province [42] 0 0
Aarhus
Country [43] 0 0
Denmark
State/province [43] 0 0
Herlev
Country [44] 0 0
Denmark
State/province [44] 0 0
Hillerød
Country [45] 0 0
Denmark
State/province [45] 0 0
Vejle
Country [46] 0 0
France
State/province [46] 0 0
Lille
Country [47] 0 0
France
State/province [47] 0 0
Montpellier
Country [48] 0 0
France
State/province [48] 0 0
Nancy
Country [49] 0 0
France
State/province [49] 0 0
Nice
Country [50] 0 0
France
State/province [50] 0 0
Paris Cedex 12
Country [51] 0 0
France
State/province [51] 0 0
Paris
Country [52] 0 0
France
State/province [52] 0 0
Pierre Benite Cedex
Country [53] 0 0
France
State/province [53] 0 0
Poitiers
Country [54] 0 0
France
State/province [54] 0 0
Saint-Étienne
Country [55] 0 0
France
State/province [55] 0 0
Salouel
Country [56] 0 0
France
State/province [56] 0 0
Toulouse
Country [57] 0 0
Georgia
State/province [57] 0 0
Batumi
Country [58] 0 0
Georgia
State/province [58] 0 0
Tiflis
Country [59] 0 0
Germany
State/province [59] 0 0
Augsburg
Country [60] 0 0
Germany
State/province [60] 0 0
Berlin
Country [61] 0 0
Germany
State/province [61] 0 0
Cologne
Country [62] 0 0
Germany
State/province [62] 0 0
Duisburg
Country [63] 0 0
Germany
State/province [63] 0 0
Erlangen
Country [64] 0 0
Germany
State/province [64] 0 0
Frankfurt am main
Country [65] 0 0
Germany
State/province [65] 0 0
Frankfurt am Main
Country [66] 0 0
Germany
State/province [66] 0 0
Freiburg
Country [67] 0 0
Germany
State/province [67] 0 0
Halle
Country [68] 0 0
Germany
State/province [68] 0 0
Heidelberg
Country [69] 0 0
Germany
State/province [69] 0 0
Kiel
Country [70] 0 0
Germany
State/province [70] 0 0
Mannheim
Country [71] 0 0
Germany
State/province [71] 0 0
Nürtingen
Country [72] 0 0
Germany
State/province [72] 0 0
Rostock
Country [73] 0 0
Germany
State/province [73] 0 0
Ulm
Country [74] 0 0
Germany
State/province [74] 0 0
Weyhe
Country [75] 0 0
Hungary
State/province [75] 0 0
Budapest
Country [76] 0 0
Hungary
State/province [76] 0 0
Szeged
Country [77] 0 0
Israel
State/province [77] 0 0
Ashkelon
Country [78] 0 0
Israel
State/province [78] 0 0
H_olon
Country [79] 0 0
Israel
State/province [79] 0 0
Jerusalem
Country [80] 0 0
Israel
State/province [80] 0 0
Nahariya
Country [81] 0 0
Israel
State/province [81] 0 0
Rehovot
Country [82] 0 0
Italy
State/province [82] 0 0
Bergamo
Country [83] 0 0
Italy
State/province [83] 0 0
Cagliari
Country [84] 0 0
Italy
State/province [84] 0 0
Firenze
Country [85] 0 0
Italy
State/province [85] 0 0
Milan
Country [86] 0 0
Italy
State/province [86] 0 0
Monza
Country [87] 0 0
Italy
State/province [87] 0 0
Padova
Country [88] 0 0
Italy
State/province [88] 0 0
Roma
Country [89] 0 0
Italy
State/province [89] 0 0
Rom
Country [90] 0 0
Italy
State/province [90] 0 0
Torino
Country [91] 0 0
Italy
State/province [91] 0 0
Udine
Country [92] 0 0
Italy
State/province [92] 0 0
Varese
Country [93] 0 0
Korea, Republic of
State/province [93] 0 0
Busan
Country [94] 0 0
Korea, Republic of
State/province [94] 0 0
Daegu
Country [95] 0 0
Korea, Republic of
State/province [95] 0 0
Guri-Si
Country [96] 0 0
Korea, Republic of
State/province [96] 0 0
Seoul
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Soeul
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Suwon-Si
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Wonju
Country [100] 0 0
Lithuania
State/province [100] 0 0
Kaunas
Country [101] 0 0
Lithuania
State/province [101] 0 0
Klaipeda
Country [102] 0 0
Lithuania
State/province [102] 0 0
Panevezys
Country [103] 0 0
Lithuania
State/province [103] 0 0
Vilnius
Country [104] 0 0
Mexico
State/province [104] 0 0
Durango
Country [105] 0 0
Mexico
State/province [105] 0 0
Merida
Country [106] 0 0
Mexico
State/province [106] 0 0
Mexico City
Country [107] 0 0
Mexico
State/province [107] 0 0
Monterrey
Country [108] 0 0
Mexico
State/province [108] 0 0
Tlalnepantla
Country [109] 0 0
Netherlands
State/province [109] 0 0
Nijmegen
Country [110] 0 0
Norway
State/province [110] 0 0
Lørenskog
Country [111] 0 0
Norway
State/province [111] 0 0
Tromsø
Country [112] 0 0
Norway
State/province [112] 0 0
Tønsberg
Country [113] 0 0
Norway
State/province [113] 0 0
Ålesund
Country [114] 0 0
Poland
State/province [114] 0 0
Grudziadz
Country [115] 0 0
Poland
State/province [115] 0 0
Knurow
Country [116] 0 0
Poland
State/province [116] 0 0
Krakow
Country [117] 0 0
Poland
State/province [117] 0 0
Kraków
Country [118] 0 0
Poland
State/province [118] 0 0
Lodz
Country [119] 0 0
Poland
State/province [119] 0 0
Malbork
Country [120] 0 0
Poland
State/province [120] 0 0
Opole
Country [121] 0 0
Poland
State/province [121] 0 0
Oswiecim
Country [122] 0 0
Poland
State/province [122] 0 0
Poznan
Country [123] 0 0
Poland
State/province [123] 0 0
Skierniewice
Country [124] 0 0
Poland
State/province [124] 0 0
Staszow
Country [125] 0 0
Poland
State/province [125] 0 0
Szczecin
Country [126] 0 0
Poland
State/province [126] 0 0
Torun
Country [127] 0 0
Poland
State/province [127] 0 0
Warsaw
Country [128] 0 0
Poland
State/province [128] 0 0
Warszawa
Country [129] 0 0
Poland
State/province [129] 0 0
Wroclaw
Country [130] 0 0
Poland
State/province [130] 0 0
Zamosc
Country [131] 0 0
Portugal
State/province [131] 0 0
Amadora
Country [132] 0 0
Portugal
State/province [132] 0 0
Braga
Country [133] 0 0
Portugal
State/province [133] 0 0
Loures
Country [134] 0 0
Portugal
State/province [134] 0 0
Santa Maria da Feira
Country [135] 0 0
Romania
State/province [135] 0 0
Bucharest
Country [136] 0 0
Romania
State/province [136] 0 0
Bucuresti
Country [137] 0 0
Romania
State/province [137] 0 0
Cluj-Napoca
Country [138] 0 0
Romania
State/province [138] 0 0
Iasi
Country [139] 0 0
Romania
State/province [139] 0 0
Timisoara
Country [140] 0 0
Romania
State/province [140] 0 0
Târgu Mure?
Country [141] 0 0
Serbia
State/province [141] 0 0
Belgrade
Country [142] 0 0
Serbia
State/province [142] 0 0
Belgrad
Country [143] 0 0
Serbia
State/province [143] 0 0
Kragujevac
Country [144] 0 0
Serbia
State/province [144] 0 0
Zrenjanin
Country [145] 0 0
Slovakia
State/province [145] 0 0
Banska Bystrica
Country [146] 0 0
Slovakia
State/province [146] 0 0
Bratislava
Country [147] 0 0
Slovakia
State/province [147] 0 0
Košice
Country [148] 0 0
Slovakia
State/province [148] 0 0
Nove Zamky
Country [149] 0 0
Slovakia
State/province [149] 0 0
Sahy
Country [150] 0 0
Sweden
State/province [150] 0 0
Stockholm
Country [151] 0 0
Sweden
State/province [151] 0 0
Uppsala
Country [152] 0 0
Sweden
State/province [152] 0 0
Örebro
Country [153] 0 0
Turkey
State/province [153] 0 0
Ankara
Country [154] 0 0
Turkey
State/province [154] 0 0
Istanbul
Country [155] 0 0
Turkey
State/province [155] 0 0
Mersin
Country [156] 0 0
United Kingdom
State/province [156] 0 0
Bury
Country [157] 0 0
United Kingdom
State/province [157] 0 0
Coventry
Country [158] 0 0
United Kingdom
State/province [158] 0 0
Darlington
Country [159] 0 0
United Kingdom
State/province [159] 0 0
Glasgow
Country [160] 0 0
United Kingdom
State/province [160] 0 0
Harrow
Country [161] 0 0
United Kingdom
State/province [161] 0 0
London
Country [162] 0 0
United Kingdom
State/province [162] 0 0
Northwood
Country [163] 0 0
United Kingdom
State/province [163] 0 0
Orpington
Country [164] 0 0
United Kingdom
State/province [164] 0 0
Reading

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
InDex Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is to evaluate the efficacy of cobitolimod treatment compared to
placebo in inducing clinical remission, in participants with moderate to severe active
left-sided UC and to evaluate the efficacy of cobitolimod maintenance treatment compared to
placebo in inducing or maintaining clinical remission at week 52, in participants with
clinical response at week 6 after induction treatment with cobitolimod.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04985968
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Raja Atreya, Professor
Address 0 0
Friedrich-Alexander University Erlangen-Nuremberg
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04985968